Scandinavian ChemoTech AB Series B (CMOTEC-B) - Total Liabilities
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has total liabilities worth Skr9.49 Million SEK (≈ $1.02 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is Scandinavian ChemoTech AB Series B's working capital to evaluate short-term liquidity relative to the company's equity base.
Scandinavian ChemoTech AB Series B - Total Liabilities Trend (2014–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Scandinavian ChemoTech AB Series B balance sheet assets.
Scandinavian ChemoTech AB Series B Competitors by Total Liabilities
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ICDS Limited
NSE:ICDSLTD
|
India | Rs30.58 Million |
|
Dnonce Tech Bhd
KLSE:7114
|
Malaysia | RM125.54 Million |
|
Swift Networks Group Ltd
AU:SW1
|
Australia | AU$16.14 Million |
|
Harper Hygienics S.A.
WAR:HRP
|
Poland | zł180.43 Million |
|
Canterbury Resources Ltd
AU:CBY
|
Australia | AU$338.28K |
|
Churchill Resources Inc
V:CRI
|
Canada | CA$1.26 Million |
|
Celsius Resources Limited
F:FX8
|
Germany | €1.07 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Scandinavian ChemoTech AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CMOTEC-B equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scandinavian ChemoTech AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scandinavian ChemoTech AB Series B (2014–2025)
The table below shows the annual total liabilities of Scandinavian ChemoTech AB Series B from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr10.01 Million ≈ $1.08 Million |
+35.32% |
| 2024-12-31 | Skr7.40 Million ≈ $796.36K |
+92.81% |
| 2023-12-31 | Skr3.84 Million ≈ $413.03K |
-50.21% |
| 2022-12-31 | Skr7.71 Million ≈ $829.61K |
+307.24% |
| 2021-12-31 | Skr1.89 Million ≈ $203.72K |
-71.98% |
| 2020-12-31 | Skr6.75 Million ≈ $726.95K |
-12.95% |
| 2019-12-31 | Skr7.76 Million ≈ $835.10K |
+235.50% |
| 2018-12-31 | Skr2.31 Million ≈ $248.92K |
-9.52% |
| 2017-12-31 | Skr2.56 Million ≈ $275.11K |
+13.94% |
| 2016-12-31 | Skr2.24 Million ≈ $241.46K |
-61.21% |
| 2015-12-31 | Skr5.78 Million ≈ $622.47K |
+29367.34% |
| 2014-12-31 | Skr19.63K ≈ $2.11K |
-- |
About Scandinavian ChemoTech AB Series B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTe… Read more